Jove
Visualize
Contact Us

Related Concept Videos

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Analysis Methods of Pharmacokinetic Data: Model and Model-Independent Approaches01:14

Analysis Methods of Pharmacokinetic Data: Model and Model-Independent Approaches

Drug disposition in the body is a complex process and can be studied using two major approaches: the model and the model-independent approaches.
The model approach uses mathematical models to describe changes in drug concentration over time. Pharmacokinetic models help characterize drug behavior in patients, predict drug concentration in the body fluids, calculate optimum dosage regimens, and evaluate the risk of toxicity. However, ensuring that the model fits the experimental data accurately...
Decision Making: P-value Method01:09

Decision Making: P-value Method

The process of hypothesis testing based on the P-value method includes calculating the P- value using the sample data and interpreting it.
First, a specific claim about the population parameter is proposed. The claim is based on the research question and is stated in a simple form. Further, an opposing statement to the claim  is also stated. These statements can act as null and alternative hypotheses:  a null hypothesis would be a neutral statement while the alternative hypothesis can have a...
Measurement of Bioavailability: Pharmacodynamic Methods01:20

Measurement of Bioavailability: Pharmacodynamic Methods

Pharmacodynamic methods provide insights into a drug's effects on physiological processes over time and play a crucial role in understanding bioavailability and therapeutic efficacy. These methods can be broadly classified into acute pharmacological and therapeutic response approaches, each with distinct mechanisms and applications.The acute pharmacological response method directly correlates a drug's physiological effects, such as ECG or pupil diameter changes, to its time course in the body.
Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis00:59

Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis

Noncompartmental analyses offer an alternative method for describing drug pharmacokinetics without relying on a specific compartmental model. In this approach, the drug's pharmacokinetics are assumed to be linear, with the terminal phase log-linear. This assumption allows for simplified analysis and interpretation of the drug's behavior in the body.
One important characteristic of noncompartmental analyses is that drug exposure increases proportionally with increasing doses. This relationship...
Comparing the Survival Analysis of Two or More Groups01:20

Comparing the Survival Analysis of Two or More Groups

Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and Cox...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Shared Ethical Responsibility of Medically and Non-medically Qualified Experts in Human Drug Development Teams.

Frontiers in pharmacology·2018
Same author

Economic comments on proposal for a novel cancer drug pricing model.

Nature reviews. Clinical oncology·2018
Same author

Fostering Competence in Medicines Development: The IFAPP Perspective.

Frontiers in pharmacology·2016
Same author

Editorial: Today's Nutrition and Tomorrow's Public Health: Challenges and Opportunities.

Frontiers in pharmacology·2016
Same author

Health economic modeling to assess short-term costs of maternal overweight, gestational diabetes, and related macrosomia - a pilot evaluation.

Frontiers in pharmacology·2015
Same author

Cost-effectiveness of prucalopride in the treatment of chronic constipation in the Netherlands.

Frontiers in pharmacology·2015
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: May 31, 2026

Operant Protocols for Assessing the Cost-benefit Analysis During Reinforced Decision Making by Rodents
07:05

Operant Protocols for Assessing the Cost-benefit Analysis During Reinforced Decision Making by Rodents

Published on: September 10, 2018

Cost-utility analysis: current methodological issues and future perspectives.

Mark J C Nuijten1, Dominique J Dubois

  • 1Ars Accessus Medica Amsterdam, Netherlands.

Frontiers in Pharmacology
|June 30, 2011
PubMed
Summary

The scientific and policy basis for using cost-effectiveness analysis in pharmaceutical reimbursement is questionable due to methodological disagreements. This review examines key concerns in cost-effectiveness data for healthcare decision-making.

Keywords:
cost–effectivenessmethodologyreimbursement criteria

More Related Videos

Signal Acquisition, Score Interpretation, and Economics of a Non-Invasive Point-of-Care Test for Coronary Artery Disease
06:16

Signal Acquisition, Score Interpretation, and Economics of a Non-Invasive Point-of-Care Test for Coronary Artery Disease

Published on: August 9, 2024

Measuring the Subjective Value of Risky and Ambiguous Options using Experimental Economics and Functional MRI Methods
13:04

Measuring the Subjective Value of Risky and Ambiguous Options using Experimental Economics and Functional MRI Methods

Published on: September 19, 2012

Related Experiment Videos

Last Updated: May 31, 2026

Operant Protocols for Assessing the Cost-benefit Analysis During Reinforced Decision Making by Rodents
07:05

Operant Protocols for Assessing the Cost-benefit Analysis During Reinforced Decision Making by Rodents

Published on: September 10, 2018

Signal Acquisition, Score Interpretation, and Economics of a Non-Invasive Point-of-Care Test for Coronary Artery Disease
06:16

Signal Acquisition, Score Interpretation, and Economics of a Non-Invasive Point-of-Care Test for Coronary Artery Disease

Published on: August 9, 2024

Measuring the Subjective Value of Risky and Ambiguous Options using Experimental Economics and Functional MRI Methods
13:04

Measuring the Subjective Value of Risky and Ambiguous Options using Experimental Economics and Functional MRI Methods

Published on: September 19, 2012

Area of Science:

  • Health Economics
  • Pharmaceutical Policy
  • Decision Science

Background:

  • Cost-effectiveness analysis (CEA) is frequently used in pharmaceutical reimbursement decisions.
  • Significant methodological debates challenge the scientific and policy validity of CEA.
  • Lack of consensus exists on key CEA issues, impacting healthcare decision-making.

Purpose of the Study:

  • To critically evaluate the scientific and policy implications of using CEA as a primary criterion for pharmaceutical reimbursement.
  • To identify and discuss key methodological concerns within CEA.
  • To explore the relevance of broader decision criteria beyond cost-effectiveness.

Main Methods:

  • Literature review focusing on methodological issues in CEA.
  • Analysis of key concerns including discounting, utility measurement, cost assessment, and modeling.
  • Discussion of alternative and complementary decision-making criteria.

Main Results:

  • Identified a lack of consensus on core methodological aspects of CEA.
  • Highlighted concerns regarding the appropriateness of incremental cost-effectiveness thresholds (Cost/QALY).
  • Underscored the need to consider social values and equity alongside economic data.

Conclusions:

  • The reliance on CEA for pharmaceutical reimbursement decisions requires critical scientific and policy re-evaluation.
  • Methodological challenges in CEA limit its current appropriateness for healthcare decision-making.
  • Integrating social values and equity is crucial for comprehensive reimbursement policies.